Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms

BackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized as a treatable cause of heart failure (HF). Advances in diagnosis and therapy have increased the number of patients diagnosed at early stages, but prognostic data on patients without HF symptoms are lacking. Moreover...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	JACC CardioOncology 2022-11, Vol.4 (4), p.442-454
Hauptverfasser:	Gonzalez-Lopez, Esther, Escobar-Lopez, Luis, Obici, Laura, Saturi, Giulia, Bezard, Mélanie, Saith, Sunil E., AbouEzzeddine, Omar F., Mussinelli, Roberta, Gagliardi, Christian, Kharoubi, Mounira, Griffin, Jan M., Dispenzieri, Angela, Vilches, Silvia, Perlini, Stefano, Longhi, Simone, Oghina, Silvia, Rivas, Adrian, Grogan, Martha, Maurer, Mathew S., Damy, Thibaud, Palladini, Giovanni, Rapezzi, Claudio, Garcia-Pavia, Pablo
Format:	Artikel
Sprache:	eng
Schlagworte:	Life Sciences Mini-Focus Issue: Amyloidosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!